Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gepotidacin - GlaxoSmithKline

Drug Profile

Gepotidacin - GlaxoSmithKline

Alternative Names: 2140944; GSK 2140944; GSK-2140944E

Latest Information Update: 15 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Class Acenaphthenes; Antibacterials; Aza compounds; Ketones; Piperidines; Pyridines; Pyrones; Small molecules
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Gonorrhoea; Urinary tract infections
  • Phase II Skin and soft tissue infections
  • Phase I Bacterial infections
  • No development reported Respiratory tract infections

Most Recent Events

  • 28 Oct 2019 No recent reports of development identified for phase-I development in Bacterial-infections(In volunteers, In adults) in USA (PO, Tablet)
  • 21 Oct 2019 Phase-III clinical trials in Gonorrhoea (In adolescents, In adults) in United Kingdom (PO) (EudraCT2018-001780-23)
  • 21 Oct 2019 Phase-III clinical trials in Gonorrhoea (In adolescents, In adults) in USA (PO) (NCT04010539)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top